Opendata, web and dolomites

NANONC SIGNED

Nanomaterials in Oncology: Exploiting the Intrinsic Cancer-Specific Toxicity of Nanoparticles.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NANONC project word cloud

Explore the words cloud of the NANONC project. It provides you a very rough idea of what is the project "NANONC" about.

mechanisms    loading    date    metastases    primarily    cuo    cytoplasm    dose    selective    toxicity    biological    tumor    therapeutic    zno    cytoplasmic    chemically    overcome    suicide    frequent    formulations    prone    destroyed    sizes    shown    multidrug    induce    kinetics    types    hereby    tool    nanomaterials    hyperthermia    trials    rate    morbidity    home    physical    clinics    society    metal    lack    re    specificity    undergoing    limiting    selectivity    full    release    degradation    clinical    primary    ag    homing    tumors    difficult    obtain    intrinsic    first    expressing    treat    fe    efficient    limited    nm    resistant    strategy    strategies    site    selectively    efficacy    gene    cancer    destroy    nms    treatment    carriers    cells    imaging    mediators    drug    rising    enhanced    once    optical    monitored    anti    doped    suffer    vehicles    cell    explore    coatings    impeding    cancers    certain    anticancer    premature    loaded   

Project "NANONC" data sheet

The following table provides information about the project.

Coordinator
KATHOLIEKE UNIVERSITEIT LEUVEN 

Organization address
address: OUDE MARKT 13
city: LEUVEN
postcode: 3000
website: www.kuleuven.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 1˙947˙519 €
 EC max contribution 1˙947˙519 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) coordinator 1˙947˙519.00

Map

 Project objective

In our current society, therapeutic strategies against cancer suffer from dose-limiting toxicity, lack of specificity and high morbidity. To overcome this, the use of nanomaterials (NMs) is rising, where several NM formulations are undergoing clinical trials or are used in clinics where the NMs are used as drug delivery vehicles or as mediators in physical anticancer methods (e.g. hyperthermia), where to date, the success rate is limited due to low tumor targeting efficacy, lack of specificity and frequent re-use of classical toxicity mechanisms.

To overcome these issues, this research program aims to exploit the intrinsic toxicity of certain types of metal-based, degradation-prone NMs (Fe-doped ZnO, Fe-doped CuO and Ag of different sizes and coatings) towards only cancer cells as a novel and generic anti-cancer tool with 1) improved efficacy against difficult to treat cancers such as multidrug-resistant cancer cells, 2) enhanced specificity and selectivity of the treatment by the intrinsic cancer cell-specific toxicity of NMs towards cancer cells. To overcome the issues related to selective delivery of the NMs, tumor-homing cells will be used that have been shown to efficiently home to primary tumors and their metastases. In practice, the NMs used show distinct degradation kinetics that primarily induce cancer-selective toxicity. To obtain efficient tumor targeting, suicide gene-expressing tumor-homing cells will be loaded with the NMs in their cytoplasm, hereby impeding premature NM degradation. The tumor homing efficacy of these cells will be monitored via optical imaging and once at the target site these cells will be chemically destroyed using the suicide gene strategy. This will release the NMs into the tumor site, where they can selectively destroy the cancer cells. This research program will be the first to explore the full potential of cancer-specific toxicity of NMs and the use of cytoplasmic loading of cells as biological carriers for efficient delivery.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANONC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANONC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

E-DIRECT (2020)

Evolution of Direct Reciprocity in Complex Environments

Read More  

REPLAY_DMN (2019)

A theory of global memory systems

Read More  

HD-Neu-Screen (2020)

HD-MEA-based Neuronal Assays and Network Analysis for Phenotypic Drug Screenings

Read More